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Abstract
The Sultanate of Oman is a rapidly developing Muslim country with
well-organized government-funded health care services, and expanding
medical genetic facilities. The preservation of tribal structures within the Omani
population coupled with geographical isolation has produced unique patterns of
rare mutations. In order to provide diagnosticians and researchers with access
to an up-to-date resource that will assist them in their daily practice we collated
and analyzed all of the Mendelian disease-associated mutations identified in
the Omani population. By the 1  of August 2015, the dataset contained 300
mutations detected in over 150 different genes. More than half of the data
collected reflect novel genetic variations that were first described in the Omani
population, and most disorders with known mutations are inherited in an
autosomal recessive fashion. A number of novel Mendelian disease genes
have been discovered in Omani nationals, and the corresponding mutations
are included here. The current study provides a comprehensive resource of the
mutations in the Omani population published in scientific literature or reported
through service provision that will be useful for genetic care in Oman and will be
a starting point for variation databases as next-generation sequencing
technologies are introduced into genetic medicine in Oman.
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Introduction
Oman is situated in the South East of the Arabian Peninsula along 
the East coast of the Arabian Gulf (Figure 1). It has its borders with 
United Arab Emirates to the North, Saudi Arabia to the West and 
Yemen to the South West. Oman is the second largest territory in the 
Arabian Peninsula with an area of 82,000 square miles and a coast-
line length of 1,300 miles. The native Omani population comprises 
around 2.2 million inhabitants, and the rate of annual population 
increase is approximately 25 per 1000. Oman has a young population 
with nearly half of the population being under 15 years. The Omani 
population is characterized by a high growth rate, large family size, 
consanguineous marriages, and the presence of genetic isolates.
Clinical genetic services were introduced in the Sultanate of Oman 
in the past decade and they have become an important compo-
nent of health care. This greatly facilitated the systematic collec-
tion of data on genetic diseases and birth defects in the past few 
decades. With the inauguration of the National Genetic Center in 
2013, the existing clinical genetic services were supplemented by 
sophisticated genetic laboratory services.
The amount of published data available on genetic disorders in the 
Sultanate is considerable. There were a few previous attempts to list 
the genetic diseases reported in Oman1–4 and to link them to specific 
population groups and geographic locations5,6, analyze population 
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structure7, and to estimate the impact of genetic disorders and birth 
defects on the community4 and summarize the genetic services 
available8. The advances in bioinformatics required to annotate 
human genomic variants and to place them in public data reposi-
tories have not kept pace with their discovery. The deposition of 
such data in the public domain is essential to maximize both their 
scientific and clinical utility9.
Hence, in the current study we present a comprehensive compila-
tion of germline mutations in nuclear genes associated with human 
disease in the Omani population.
Materials and methods
The wealth of genetic variant data in Omani nationals was col-
lected from multiple sources which form a basis for research into 
genetic conditions reported from Oman. Multiple sources of data 
were reviewed to form repository of mutations in Omani nationals 
introduced in this paper. The sources of data included:
(1) 1993–2015 records of patients consulted by clinical geneticists 
of the Royal Hospital, the largest tertiary hospital in Oman;
(2) 2008–2015 publications curated from PUBMED on birth defects 
and genetic conditions in Omani nationals. The keywords used 
were: “Oman”, “Genetic disorders”, “Birth defects”, “mutations”;
(3) 2012–2014 commercial laboratories referral registry at the 
Royal Hospital for the samples tested overseas.
(4) The internal genetic variant repository of the National Genetic 
Center <<HTTP://ogvd.net>>;
The data presented in this article was manually curated. The 
OMIM identifiers, Phenotype MIM accession numbers, Phenotype 
name (OMIM), mutation descriptions, and relevant publications 
with PMID numbers were all collected from the NCBI database 
repository. All unavailable through PubMed mutation details were 
checked with ClinVar, LOVD and CentoMD. The details of unpub-
lished mutations are not included in the present study and feature in 
Table 2 as “Novel mutations”.
Results
In this study, a wide range of genetic conditions with known muta-
tions collected in Omani nationals were analysed. The disease 
classifications are comprised of 44 gene variants causing neurode-
velopmental disorders, 21 inborn errors of metabolism, 13 endo-
crinopathies, 15 skeletal dysplasias, nine disorders of the immune 
system, four hereditary blood disorders as well as other National 
groups (Table 1).
In total more than 150 rare genetic disorders were listed in Table 2 
and Table 3 with relevant OMIM numbers, PubMed ID (PMID), 
Gene/Locus name, nucleotide(s) change(s) and the source of the 
data (PubMed ID Number/ OMIM/ClinVar/LOVD/CentoMD). 
The names of genetic conditions in Table 2 are stated as found in 
OMIM “Phenotype-Gene Relationships” table as “Phenotype” 
arranged in alphabetical order. In Table 3, we present a separate list 
of 69 known mutations (11–15) that were collected through service 
provision at the Hemoglobinopathy Laboratory at the National 
Genetic Center in Oman.
For the majority (85%) of rare disorders presented in Table 2, data 
was derived from publications. The original mutations identified for 
the first time in Omani population constitute more than half of rare 
disease data presented in Table 2.
Discussion
Soon after the completion of the Human Genome Project in 
2003, it was clear that the genetic data collected until then pre-
sented only a glimpse of the complexity of the human genome and 
the significance of genetic variants in human disease. Since then, 
genetic researchers have unearthed innumerable variants that are 
not only individual-specific; but also ethnicity-, population- and 
country-specific. Human genetic variation databases have sig-
nificant implications for both diagnostic and predictive medicine. 
Often, the pathogenicity of rare mutations is primarily assessed 
through multiple reports of occurrence in diseased patients that are 
documented and routinely updated in mutation databases. Given the 
fact that gene mutations and their frequencies in many Mendelian 
disorders differ widely between different ethnic groups, even within 
a country, national databases are highly valuable resources for stud-
ies on disease-gene associations, population diversity and genetic 
history10.
The catalog of Omani mutations presented here will therefore 
represent a valuable resource that may guide mutation analysis in 
Omanis suspected of having genetic disease. Unique circum-
stances in Oman with government-funded comprehensive health-
care throughout the country, and the national coverage for clinical 
genetics has made the present study possible. Future efforts will be 
required to extend this database to cover the full spectrum of muta-
tions and population specific variants.
The disease-associated mutation data presented (Table 1, Table 2, 
Table 3) show a considerable proportion of novel disease genes as 
well as novel genetic variants within the Omani population. This was 
expected due to the presence of inbred and geographically isolated 
communities, the practice of consanguineous marriages, all of which 
have tended to skew the allelic spectrum toward rare and private 
variants within the Omani population. In addition to this, the list of 
genetic variants also reveals known mutations that were previously 
reported in certain non-Omani populations, thereby reflecting the his-
toric genetic admixture that occurred in Oman, along the trade routes 
of a once powerful Omani empire and its foreign colonies. Many of 
the mutations reported are unique to the Omani population, suggest-
ing a founder effect.
The interest in genetic testing is growing among physicians aiming 
to provide better medical care and genetic disease prevention. The 
data collected largely represent mutations of rare autosomal reces-
sively inherited disorders in Oman. The mutation data in Table 2 
can be searched by OMIM number, or by disease name. The 
names of diseases in Table 2 were chosen as described in OMIM in 
“Phenotype-Gene Relationships” table as “Phenotype” in order to 
ease finding specific genetic disorders by name.
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Table 1. Range of genetic conditions with known mutations in Omani nationals (details presented in Table 2 
and Table 3).
Range of Genetic Conditions with 
















              Beta-Globin 1 33 2 3
              Alpha-Globin 2 22 3 2
              Delta-Globin 1 14 3 0
Other hemolytic and hemorrhagic disorders 3 5 3 2
Neurodevelopmental disorders
         Conditions with intellectual disability 20 23 9 7
Primary Microcephaly 5 5 2 2
Epileptic syndromes 2 2 0 1
Neurodegenerative conditions 6 7 1 1
Syndromic ciliopathies 6 7 5 3
Hereditary spastic paraplegias 5 6 4 3
Neuropathies and neuromuscular 
disorders 8 13 1 1
Arthrogryposis 3 3 2 2
Inborn errors of metabolism 21 28 21 2
Endocrine disorders 13 28 2 5
Intrahepatic cholestasis and gut anomalies 4 8 3 0
Disorders of the immune system 9 15 3 4
Familial cancers 4 6 1 0
Skeletal dysplasias and osteodysplasias 15 23 6 8
Cardiogenetic conditions 2 2 1 1
Renal disorders and dysplasias 6 13 0 1
Skin, nails, and hair disorders 6 10 0 3
Cutis laxa syndromes 2 7 0 3
Ophthalmological diseases including 
blindness
5 8 0 2
Congenital deafness 1 3 0 1
Congenital lipodystrophies 5 5 0 1
Cystic fibrosis 1 4 1 2
Total 156 300 83 58
Extensive genetic studies were performed in Oman for Genetic Blood Disorders and various conditions leading to 
intellectual disabilities, mental and physical handicap.
Page 4 of 17
F1000Research 2015, 4:891 Last updated: 26 OCT 2015
Table 2. List of disease-associated mutations in Omani nationals.


















3 Adrenal hyperplasia, congenital, due to 17-hydroxylase deficiency 202110 609300 CYP17A1
c.287G>A 
p.Arg96Gln 24498484








6 Alport syndrome, autosomal recessive 203780 120070 COL4A3 R1215X(CGA>TG 14582039







8 Alstrom syndrome *606884 203800 ALMS1 Novel mutation 17594715
















11 Arterial tortuosity syndrome 208050 208050 SLC2A10 243C-G 16550171
12 Arthrogryposis, renal dysfunction, and cholestasis 1 *608552 208085 Vps33B c.350delC 15052268
13 Autoimmune Lymphoproliferative Syndrome (Type A) 601859 601853 FAS c.232 del G, exon3 8787672
14 Bardet-Biedl Syndrome 9 (BBS9) *615986 615986 PTHB1 IVS 17/IGTA variant 17106446




16 Brain Calcifications/Coat’s like syndrome/Rajab syndrome *613658 613658 NA Linkage to 2q36.3 19161147
17 Breast cancer 114480 114480 BRCA 1 2080insA 18340530
18 Carbamoylphosphate synthetase I deficiency *238970 237300 CPSI c.1590dupT 22106832
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19 Carnitinepalmitoyl carboxylase deficiency *600650 1p32.3 CPT2 gene
detectable mutations 
were excluded ClinVar




21 Ceroid lipofuscinosis, neuronal, 2 (CLN2) *204500 607998 TPP1 positive linkage 17690061
22 Charcot-Marie-Tooth disease, type 4A 214400 214400 GDAP1 Start-codon mutation 22200116
23 Cohen Syndrome (COH 1) *216550 216550 VPS13B 7934G>A 15173253







25 Cholestasis intrahepatic *243300 243300 ATP8B1 (exon 15) het del CentoMD; 15239083
26 Cholestasis, benign recurrent intrahepatic, 2 605479 605479 ABCB11
c.149G.A LOVD; 
CentoMDc.1416T.A
27 Cholestasis, progressive familial intrahepatic 3 602347 602347 ABCB4 c.2800G>A LOVD









30 Chronic granulomatous disease due todeficiency of NCF1 *233700 233700 NCF1
c.579G>A 24446915; 
24446915Novel mutation




























36 Diabetes mellitus, permanent neonatal 606176 606176 ABCC8 c.4480C>T 9769320
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*226900 NA 15q26 Linkage D15S205/ D15S966 11389160







224900 224900 EDAR 718delAAA 20979233
41 Enhanced S-cone syndrome (Golden- Favre syndrome) *268100 268100 NR2E3 c.1117 A>G 24891813
42 Ellis Van-Creveld *225500 225500 EVC
Frameshift in exon 13 17024374; 
20184732Novel mutation
43 Epilepsy, progressive myoclonic 2B (MELF) 254780 254780 NHLRC1 c.468_469delAG 18263761
44 Escobar syndrome *265000 265000 CHRNG γ78dup(3) 16826520
45 Ethyl Malonic Aciduria 608451 608451 ETHE1 c.487C>T Cento MD; 14732903
46 Factor X deficiency/Familiar CRM *227600 227600 F10 c.381G>A 12574802








49 Familial Mediterranean fever, AR *608107 247100 MEFV c.442G>C CentoMD, ClinVar






51 Gastrointestinal defects and immunodeficiency syndrome 243150 243150 TTC7A Q712X 25534311




53 Geroderma osteodysplastica Hereditatria *231070 231070 GORAB 367G-T 19648921
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56 Griscelli syndrome, type 2 607624 607624 RAB27A Novel mutation NA
57 Hemolytic uremic syndrome, atypical, susceptibility to, 3 612923 612923 CFI c.1332A>G CentoMD
58 Hermansky-Pudlak syndrome 2 608233 608233 AP3B1 c.12_13delTA 16537806 8042664
59 Hyperexplexia *149400 149400 GLRA1 c.593G>C 22264702

















62 Hyperinsulinemic Hypoglycemia, familiar, 5 *147670 609968 INSR Novel mutation NA
63 Hypercholesterolemia, familial *143890 143890 LDLR c.272delG 23162007; 24249837
64 Hyperlipoproteinemia, type 1D (chylomicronemia) *615947 615947 GPIHBP1 C.149G>A 22106832
65 HYPERPHENYLALANINEM IA BH4- deficient C, (HPABH4C) *261630 261630 QDPR Novel mutation NA
66 Hyperoxaluria, primary, type 1 259900 259900 AGXT c.33-34insC CentoMD; 21612638





241410 241410 TBCE c.155-166del12bp 19491227
69 Hypophosphatasia, childhood 241510 241510 ALPL c. 98C>T 25023282
70 Huntington Disease 143100 143100 HTT 41-54 repeats 25689972
71 HUNTINTON-LIKE DISEASE *605613 NIL HIP1R Novel mutation NA




73 Insensivity to pain, congenital, with anhydrosis (HSAN IV) 256800 256800 NTRK1 Novel mutation NA
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75 Jouber Syndrome 1 (JBTS1) *213300 213300 INPPSE c.1546C>T in exon 7 19668216
76 Joubert syndrome 5 *610142 610188 CEP 290 c.21G>T exone1 19764032
77 Kindler Syndrome (poikiloderma) *173650 173650 KIND1 R271X 12789646
78 Leprechaunism 147670 246200 INSR Single nucleotide del in exon 10
OMIM: 
147670.0028
79 Leukodystrophy, hypomyelinating, 2 (Pelizaeus-Merzbacher-Like Disease 1) *608803 608804 GJC2 c.-20+1G>C 23143715
80 LCHAD deficiency 600980 609016 HADHA Novel mutation NA
C Lipodystrophy, congenital generalized, type 4 *613327 613327 PTRF-Cavin c.160delG 20300641
82 Lipodystrophy, congenital generalized, type 1 (BSCL1) 608594 608594 AGPAT2
Homozygosity 
D9S1818-DS1826 11916958
83 Lipodystrophy, congenital generalized, type 2 (BSCL2) 606158 269700 SEIPIN
Homozygocity 1883- 
4136 12116229,
84 Lipodystrophy, familial partial, 2 150330 151660 LAMIN A\C Homozygosity 3757 12116229
85 Limb Girdle muscular dystrophy 2B;LGMD2B (Miyoshi myopathy) 254130 254130 DYSF C :526C>T 10469840
86 Lissencephaly LIS 4A 300121 300121 DCX exon 5: 11175293
87 Loeys-Dietz syndrome, type 1 609192 609192 TGFBR1 or 2 Positive linkage 16928994
88 Long QT syndrome 1(LQT1) 192500 192500 KCNQ1 1388G>C 15159330




90 Mental retardation, autosomal recessive 43 (MRT 43) *615817 615817 KIAA1033
c.3056C-G 
transversion in exon 29 2149877
91 Mental Retardation, autosomal recessive *602810 602810 HIST 3H3 c. R130C 21937992
92 Mental Retardation Autosomal Recessive, epilepsy, autism *NA NA DEAF1 c.997+4A>C 26048982
93 Meckel Gruber syndrome (MKS 3) *607361 607361 TMEM67 c. 383-384AC del 16415887
94 Microcephaly with simplified gyral pattern *603807 603807 NA Excluded known loci 17975804
95 Microcephaly 3, primary, autosomal recessive 604804 604804 CDK5RAP2 c. E234X 22887808
96 Microcephaly 5, primary, autosomal recessive 608716 608716 ASPM c.9153_9154 del ins A 15045028




98 Microcephalic osteodysplastic primordial dwarfism, type II *210720 210720 PCNT Maps to 21q22.3 18174396






100 Mucopolysaccharidosis type IVB (Morquio) 253010 252010 GLB1 c.1420G>C CentoMD
101 Multiple endocrine neoplasia IIA (MEN2A) 171400 171400 RET c.1900T>C 8103403
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103 Multiple pterygium syndrome, lethal type *100730 253290 CHRNG c.ARG448TER 16826520
104 Myotonic Dystrophy 1 605377 160900 DMPK Expansion, >rpts 1allele 8036515
105 Nephrotic syndrome, type 1 *256300 25630 NPHS1
(121delCT) ; CentoMD; 
9660941c.218C>T





107 Noonan syndrome 1 (NS1) 163150 163150 PTPN11 c.218C>T 12161469
108 Niemann-Pick disease, type C1 (NPC1) *257220 257220 NPC1 c.3362T>G Cento MD
109 Osteogenesis imperfecta, type VIII 610915 610915 LEPRE1
c.2075-1G>A 24498616; 
LOVDc.1170+9G>A
110 Osteogenesis imperfecta, type VI 613982 613982 SERPINF1 c.-9+2dup 23054245
111 Osteopetrosis, infantilile malignant *259700 259700 TCIRG1 c.-XY_-YZdel 23685543
112 Orofaciodigital syndrome V *174300 174300 DDX59 c.1600G>A 23972372










115 Pelger-Huet anomaly *169400 169400 LBR del 6 BP in splice site intron 12 21326950





117 Pituitary hormone deficiency, combined, 3 *221750 221750 LHX3 3,088-bp deletion 18407919
118 Pontocerebellar Hypoplasia type III *608027 608027 PCLO nonsense mutation of PCLO (piccolo) gene 25832664
119 Polycystic Kidney and Hepatic Disease 1 263200 263200 FCYT c.107C>T 11919560
120 Polycystic liver disease 608648 608648 SEC63 Del in promoter region
24886261 
25165181
121 Rabson-Mendenhall syndrome 262190 262190 INSR c.671_685dup CentoMD; 22824672
122 Rajab Syndrome *613658 613658 NA linkage D2S351/ D2S2390 19161147




124 Retinitis pigmentosa-12, autosomal recessive *604210 600105 RABS 1 7 mutations 24512366
125 Retinitis pigmentosa 37 *604485 268100 NR2E3 p.D406G 24891813
Page 10 of 17
F1000Research 2015, 4:891 Last updated: 26 OCT 2015






126 Rett Syndrome 312750 312750 MECP2 c.880C>T ClinVar
127 Robinow syndrome, autosomal recessive *268310 268310 ROR 2
c.1504C>T 10932186; 
19640924c.1324C>T
128 Severe combined immunodeficiency, B cell-negative 179615 601457 RAG1 c.1187G>A ClinVar
129 Spinal Muscular Atrophy (SMN1) 253300 253300 SMN1
del exons 5, 6, 8 ; 15000810; 
17940251Del 5q13.2 in exon 7
130 Spastic paraplegia 18, autosomal recessive (IDMDC) *611225 611225 ERLIN 2
(D8S1820 and 
D8S532) 16636240






612319 612319 FA2H c.235A>C 20104589
133 Spastic paraplegia 54, autosomal recessive *615033 615003.0005 DDHD2 1546C-T transition 23176823
134 Spastic paraplegia, ataxia, and mental retardation *607565 607565 GRID2 Novel mutation NA
135 Split-hand/foot malformation with long bone deficiency 3 *612576 612576 BHLHA9 microduplications 22147889
136 Spondylometaepiphyseal dysplasia, short limb-hand type (SMED-SL) *271665 271665 DDR2 c.2468_2469del CT 24725993
137 Spondyloepiphyseal dysplasia Omani type with congenital joint dislocations *143095 1439095 CHST3 c. 911G>A 15215498





164500 164500 ATXN7; Repeat expansion of ATXN7 gene ClinVar
140 Schwartz-Jampel syndrome, type 1 *255800 255800 HSPG-2 IVS64DS, A-G, +4; c.1532C>T 11101850




142 Systemic Lupus Erythematosus (SLE), susceptibility. *125505 152700 DNASE1L3 G38OR ; 22019780




144 Three-M syndrome 1 *273750 273750 CUL
c2434C>T 19225462
690 ins C 19877176
145 Three M Syndrome 2 *610991 612921 OBCL1 844ins68 19877176
146 Thrombosis, hyperhomocysteinemic *236200 236200 CBS c.807C>A; 16432849
147 Thyroid hormone resistance, autosomal recessive 190160 274300 TRB2
del in exon10 1991834
Novel mutation NA
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The number of collected mutations among different disease groups 
(Table 1) reflect the frequency of disorders in the Omani popula-
tion, the burden caused by genetic diseases4, and the interests of 
individual clinicians in genetic testing.
The knowledge of the genetics of Hemoglobin disorders is among 
the best in Oman due to national preventive programs and research 
starting from the 1990s. It is not surprising that around a third 
of all mutations known in Omani population to date are in four 
genes causing Hemoglobin disorders (Table 1, Table 3). The birth 
prevalence of infants with a hemoglobin disorder was recorded as 
3.5–4.7/1,0007,11. The frequency of hemoglobin disorders in Oman 
is among the highest in the world, and may reflect natural selec-
tion due to advantage for survival, in the heterozygous state, against 
Table 3. Mutations associated with hemoglobin disorders in the Omani population.
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malaria. Around 10% of Omani nationals are carriers of the allele 
for sickle cell anemia, 2–3% carry an allele for Beta-thalassemia 
and 45% are carriers of an alpha-thalassemia allele12–15.
Genetic disorders causing disabilities and handicap are of great 
concern. These are different groups of rare disorders leading to 
intellectual disability or physical handicap requiring detailed clini-
cal classification, genetic testing, research and preventive measures. 
The high prevalence of birth defects and genetic conditions in 
Omani communities causes social, psychological and financial dif-
ficulties4. The development and use of national mutation data is of 
importance to Omani medical care because it not only allows the 
genetic burden of disease to be quantified, but also provides diag-
nosticians and researchers access to an up-to-date resource that will 
assist them in their daily clinical practice and biomedical research9. 
National databases for genetic variants are also significant from the 
perspective of preventive healthcare. There is a significant corre-
lation between the occurrence of rare genetic variants associated 
with Mendelian disease and the burden of morbidity from complex 
diseases within a population. Heterozygous carriers for recessive 
disease genes do not manifest the recessive disease but may be at 
risk of developing complex trait conditions with some similarity in 
phenotype. For example, heterozygote carriers of mutations in the 
ataxia telangiectasia gene locus are reportedly susceptible to breast 
cancer16, and heterozygote carriers of mutations in the glucocer-
ebrosidase (GBA) gene causing Gaucher disease are at an increased 
risk for Parkinson disease17,18. Hence, the collection of genetic vari-
ant data in national databases will contribute significantly to the 
prevention of genetic diseases in the population and might greatly 
impact the management of complex trait diseases in the future. 
Genetic scientists and international consortiums studying human 
genetic variation are increasingly interested in dissecting the inter-
play between genetic makeup and environmental influences on the 
pattern of diseases worldwide. Current research is expected to cre-
ate a foundation for the national data online for the benefit of Oman 
Healthcare.
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 Milan Macek
Department of Biology and Medical Sciences, Charles University in Prague, Prague, Czech Republic
This is an excellent pioneering piece of work which presents an authoritative overview of a representative
mutation analysis (300 pathogenic variants in over 150 monogenic disorders) in a large cohort of Omani
patients. Methodology is state of the art, collaboration with colleagues at Charite Berlin commendable and
results which are important for DNA diagnostics in the Omani population, and beyond. The conclusions,
are relevant and directly applicable. I fully approve this article without any comments to the Authors.
Importantly, data are also freely accessible online.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 Shaillay Dogra
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Its useful to have region/country specific databases that present a better representation of the prevalence
and incidence of region specific diseases and health issues. Putting such data in context of whats known
globally shall help in better interpreting whats peculiar to local population and possibly raise some
interesting questions on why so? For example, is it the genetic structure or something in the environment?
Some specific comments follow:
Authors mention existence of tribal structures, consanguineous marriages etc in Omani society. Is
it possible to delineate the effects of these factors on the reported mutations? For example, is this
reported in the papers that the authors have collated data from and have the authors noted this
aspect in their database?
 
How does the mutation data reported here compare with mutation patterns or frequency seen in
other populations? Do the authors provide information on this or link out to other similar resources
from other countries? If a physician in Oman is looking up some mutation from this database and
wants to know if this is something specific to Oman or is a more general mutation found in other
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wants to know if this is something specific to Oman or is a more general mutation found in other
populations too, would this information appear automatically in the database; or could they perform
a manual search of the database?
 
Do the authors want to comment about any data privacy issues that maybe associated with such a
database, if any and to what extent?
 
Are there any attributes on quality of data in the database? perhaps based on the technique used
in the original paper or some other measure some quality metric can be assigned to the mutation
information recorded in the database?
 
It would be helpful if authors were able to illustrate out a case or two on how they expect a doctor in
Oman to be able to use this database in a real clinical setting; to illustrate the usefulness of the
database from a simple collection of data to something that can be used on a more regular basis
by doctors in clinical setting.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 Prajnya Ranganath
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The paper is well-written and though it does not present any new findings, it can be used as a
reference database for Omani mutations.
 
There are a few suggestions for the authors:
a. Standard HGVS nomenclature should be followed for all the mutations and the authors should
preferably stick to one format i.e. either DNA or protein notation. There is no uniformity in the
present nomenclature followed in Table 2.
b. Number of patients in whom each mutation was found, should be indicated – this would give an
idea about any preponderance of specific mutations in this population.
c. Functional validation studies, if available, or at least the mutation prediction scores should be
mentioned for the novel sequence variants identified, which will help create a comprehensive
database of new likely-pathogenic variants. Again, if the number of patients in whom each of these
novel variants were identified is mentioned, we will get an idea as to whether these novel variants
were present in more than one case and we can get further proof of the pathogenicity of these
mutations.
d. It would also be interesting to see if there is any ethnic group-wise preponderance of genetic
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2.  
d. It would also be interesting to see if there is any ethnic group-wise preponderance of genetic
diseases or mutations in the various subsets/ tribes/ regional groups that constitute the Omani
population.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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